Report: Nonvascular ablation use poised to soar

The market for ablation devices stands to grow the most among all nonvascular interventional radiology devices in the U.S. over the next several years, the Millennium Research Group concludes in a new report. The analyst firm sees the overall ablation device market in this space--a sector that include radiofrequency ablation, cryoablation and microwave ablation devices--hitting $295 million by 2017. What's the driver here? These devices are less invasive than surgery as a way to treat liver, prostate, kidney and lung cancer, Millennium notes, something that is relevant as those soft-tissue cancers rise in frequency. And their use benefits a number of smaller medical devices in the space, the report notes, including AngioDynamics and Microsulis. Release

Suggested Articles

Sherlock Biosciences teamed up with Cepheid to help develop its CRISPR-based molecular diagnostic tech in oncology, infections and the coronavirus.

The spine surgery company ATEC has moved to acquire Paris-based EOS imaging, makers of FDA-cleared scanners and 3D orthopedic planning software.

Digital molecule designer Insilico Medicine has launched a new preclinical research program focused on treatments for brain cancer.